Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Objective: This study aimed to evaluate the treatment response, survival profiles, prognostic
factors and adverse events of anlotinib in treating advanced non-small cell lung cancer …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Purpose Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study
aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer …

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit
both tumor angiogenesis and signal transduction pathways associated with proliferation …